RecruitingNot ApplicableNCT05890781

Engineering Immune Organoids to Study Pediatric Cancer

Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)


Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Enrollment

108 participants

Start Date

May 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)


Eligibility

Max Age: 25 Years

Inclusion Criteria10

  • Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
  • Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
  • Brain tumors
  • Renal tumors
  • Neuroblastoma
  • Sarcomas
  • Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  • Affiliated to a social security system or beneficiary of the same.
  • Adult patient or parents/guardians incapable/incapable of giving its/their consent
  • Patients deprived of their liberty by a judicial or administrative decision

Interventions

PROCEDURESkin biopsy

Skin biopsy

PROCEDUREFresh tumor sample

Fresh tumor sample

BIOLOGICALBlood sample

Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

PROCEDUREHealthy tissue from the tumor

Healthy tissue from the tumor site whenever possible

PROCEDURESpinal cerebrospinal fluid (SCF)

Spinal cerebrospinal fluid (SCF) whenever possible


Locations(2)

Gustave Roussy

Villejuif, France

Hopital Necker

Paris, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05890781


Related Trials